NYSE - Delayed Quote USD

Merck & Co., Inc. (MRK)

126.94 +1.16 (+0.92%)
At close: April 22 at 4:00 PM EDT
127.02 +0.08 (+0.06%)
Pre-Market: 6:43 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
60,115,000.00
60,115,000.00
59,283,000.00
48,704,000.00
41,518,000.00
Cost of Revenue
16,126,000.00
16,126,000.00
17,411,000.00
13,626,000.00
13,618,000.00
Gross Profit
43,989,000.00
43,989,000.00
41,872,000.00
35,078,000.00
27,900,000.00
Operating Expense
41,035,000.00
41,035,000.00
23,590,000.00
21,879,000.00
22,352,000.00
Operating Income
2,954,000.00
2,954,000.00
18,282,000.00
13,199,000.00
5,548,000.00
Net Non Operating Interest Income Expense
-781,000.00
-781,000.00
-805,000.00
-770,000.00
-772,000.00
Other Income Expense
-284,000.00
-284,000.00
-1,033,000.00
1,450,000.00
1,087,000.00
Pretax Income
1,889,000.00
1,889,000.00
16,444,000.00
13,879,000.00
5,863,000.00
Tax Provision
1,512,000.00
1,512,000.00
1,918,000.00
1,521,000.00
1,340,000.00
Net Income Common Stockholders
365,000.00
365,000.00
14,519,000.00
13,049,000.00
7,067,000.00
Diluted NI Available to Com Stockholders
365,000.00
365,000.00
14,519,000.00
13,049,000.00
7,067,000.00
Basic EPS
0.14
0.14
5.73
5.16
2.79
Diluted EPS
0.14
0.14
5.71
5.14
2.78
Basic Average Shares
2,537,000.00
2,537,000.00
2,532,000.00
2,530,000.00
2,530,225.83
Diluted Average Shares
2,547,000.00
2,547,000.00
2,542,000.00
2,538,000.00
2,541,000.00
Total Expenses
57,161,000.00
57,161,000.00
41,001,000.00
35,505,000.00
35,970,000.00
Net Income from Continuing & Discontinued Operation
365,000.00
365,000.00
14,519,000.00
13,049,000.00
7,067,000.00
Normalized Income
861,910.00
861,910.00
16,278,819.00
11,470,617.41
6,590,522.00
Interest Income
365,000.00
365,000.00
157,000.00
36,000.00
59,000.00
Interest Expense
1,146,000.00
1,146,000.00
962,000.00
806,000.00
831,000.00
Net Interest Income
-781,000.00
-781,000.00
-805,000.00
-770,000.00
-772,000.00
EBIT
3,035,000.00
3,035,000.00
17,406,000.00
14,685,000.00
6,694,000.00
EBITDA
6,907,000.00
6,907,000.00
21,315,000.00
17,899,000.00
10,180,000.00
Reconciled Cost of Revenue
16,126,000.00
16,126,000.00
17,411,000.00
13,626,000.00
13,618,000.00
Reconciled Depreciation
3,872,000.00
3,872,000.00
3,909,000.00
3,214,000.00
3,486,000.00
Net Income from Continuing Operation Net Minority Interest
365,000.00
365,000.00
14,519,000.00
12,345,000.00
7,067,000.00
Total Unusual Items Excluding Goodwill
-629,000.00
-629,000.00
-1,993,000.00
982,000.00
618,000.00
Total Unusual Items
-629,000.00
-629,000.00
-1,993,000.00
982,000.00
618,000.00
Normalized EBITDA
7,536,000.00
7,536,000.00
23,308,000.00
16,917,000.00
9,562,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-132,090.00
-132,090.00
-233,181.00
107,617.41
141,522.00
12/31/2020 - 1/2/1962

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BMY Bristol-Myers Squibb Company
49.14
+0.43%
 
ABBV AbbVie Inc.
167.89
+0.89%
 
AMGN Amgen Inc.
271.91
+1.11%
 
PFE Pfizer Inc.
26.26
+1.00%
 
LLY Eli Lilly and Company
731.33
+0.69%
 
JNJ Johnson & Johnson
149.12
+0.82%
 
GILD Gilead Sciences, Inc.
66.95
+0.28%
 
OGN Organon & Co.
18.00
+1.01%
 
AZN AstraZeneca PLC
70.13
+2.30%
 
GSK GSK plc
40.59
+2.11%